Phase II study of irinotecan and cetuximab given every 2 weeks as second-line therapy for advanced colorectal cancer.
Carneiro BA, Ramanathan RK, Fakih MG, Krishnamurthi SS, Lembersky BC, Stoller RG, Lancaster SL, Pinkerton RA, Crandall TL, Schmotzer AR, Potter DM, Bahary N.
Carneiro BA, et al. Among authors: ramanathan rk.
Clin Colorectal Cancer. 2012 Mar;11(1):53-9. doi: 10.1016/j.clcc.2011.05.003. Epub 2011 Aug 2.
Clin Colorectal Cancer. 2012.
PMID: 21813336
Clinical Trial.